IMNR – The Immune Response Corporation
StockGuru Profile IMNR
| The Immune Response Corporation Secures Key Partners for Launch of Phase II Trial of NeuroVax(TM) In Patients with Multiple Sclerosis |
200 Patient Trial of Investigational Vaccine to Treat MS on Track to Initiate Patient Enrollment Before Year’s End
The Immune Response Corporation has entered into an agreement with Accelsiors CRO & Consultancy Services, a clinical research organization (CRO) with extensive experience in conducting multiple sclerosis (MS) trials, to oversee the 200-patient Phase II trial of NeuroVax(TM), an investigational T-cell receptor (TCR) peptide vaccine for the treatment of MS.
In November IMNR in Budapest, Hungary, IMNR began its trial launch meeting with investigators participating in the trial. IMNR expects patient enrollment of the multi-center, randomized, double-blind trial to begin shortly. NeuroVax(TM) may represent a significant advance in the treatment of Multiple Sclerosis( MS), which affects more than 2.5 million people worldwide, including more than 400,000 in the United States.
Successful Clinical Trials — means finding partners for marketing an easy task.
Biotech Back in Favor Big Time
“Momentum for biotech companies and stocks continues to build…in this final quarter of the year on a high note, with one of its best monthly performances of 2006,” said Steven Burrill, chief executive of Burrill & Co, a San Francisco, USA-based global life sciences group the principal activities of which are in venture capital, merchant banking and media.
“Biotech is riding a wave of heightened investor enthusiasm driven by an increase in M&A activity, significant clinical data reported broadly and excellent third-quarter financial reports,” Mr Burrill added.
“Historically, the fourth quarter has always been a good one for biotech and so there is every reason to believe that it is on target to make up for the beating suffered during the first two quarters of 2006. The biotech industry’s aggregate market cap at the end of October was just over $488.0 billion and, by the end of the year, it could reach a new record high,” he stated.
Fanning the flames of positive investor sentiment was the Dow Jones finally breaking through the psychological 12,000 barrier, closing the month up almost 3.5%. The Burrill Biotech Select Index posted another solid gain of 6% this month, well ahead of the Nasdaq (up 4.8%) and the Dow.
While it is the biotechnology sector’s elite companies such as Amgen and Genentech that continue to impress the market, it was the Burrill Mid-Cap Biotech Index that captured the headlines in October with a huge 10% jump in value. The Index is now up 15% year-to-date and set to lead all indicators in much the same way as the Burrill Biotech Select Index did in 2005.
Successful clinical trials will translate into increased interest in IMNR.
For further information contact:
ROI Group Associates
39 Broadway; NY, NY 10006
212.495.0744
MDodge@roiny.com
Source:
Pharma Marketletter
IMNR — Immune Response Corp. (The)
5931 Darwin Court
Carlsbad, CA 92008
Website: http://www.imnr.com
Phone: 760-431-7080
Forward Looking Statement and Safe Harbor: Any information regarding The Immune Response Corporation (”IMNR”) in this communication is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO ITS OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. ROI Group Associates, Inc. (”ROI”) is the investor relations counsel for IMNR and accepts compensation from the IMNR for this effort, including a monthly cash retainer and restricted stock. Under the terms of its investor relations Service Agreement, ROI has agreed not to sell any of the IMNR restricted stock received as compensation under the Service Agreement during the entire term of its engagement as IMNR’s investor relations counsel pursuant to this Service Agreement. ROI shall be under no obligation to update readers about any restrictions on its trading activities regarding IMNR.
In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.
Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.
Disclosure: Pentony Enterprises LLC was compensated $50,000 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .